8-K: Know Labs Upgrades to OTCQB Venture Market, Trading Under Symbol 'KNWN'

Know Labs, Inc. announces its common shares have been approved for trading on the OTCQB Venture Market under the ticker symbol 'KNWN', effective February 26, 2025.

Summary

• Know Labs, Inc. has been approved to have its common shares quoted on the OTCQB Venture Market under the ticker symbol KNWN, effective February 26, 2025.
• The company's trading symbol was temporarily affixed with a 'D' for 20 days, effective February 19, 2025, following the announcement of a reverse stock split by FINRA on February 18, 2025.
• The OTCQB is recognized by the SEC as an 'established public market' for entrepreneurial and development-stage companies.
• OTCQB listing requires companies to be current in financial reporting, pass a minimum bid price test, and undergo annual verification and certification.
• Know Labs' platform technology uses radio frequency dielectric spectroscopy (RFDS) to capture a unique molecular signature.
• The company's first expected application of the technology will be a non-invasive glucose monitor, which will require FDA clearance.
• Other products developed through the Know Labs Technology License (KTL) program may not require prior FDA approval.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's upgrade to the OTCQB market, which is expected to improve liquidity and visibility. However, the need for FDA clearance for the glucose monitor introduces uncertainty.

Positives

• Listing on the OTCQB Venture Market is expected to increase transparency and liquidity for Know Labs.
• The company's RFDS technology has the potential for various applications, including non-invasive glucose monitoring.
• The OTCQB is recognized as an 'established public market' by the SEC.
• The company believes its patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests.

Risks

• The non-invasive glucose monitor requires FDA clearance before it can be introduced to the market.
• Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
• The company's filings with the SEC contain additional risk factors.

Future Outlook

The company anticipates the first application of its RFDS technology to be a non-invasive glucose monitor, pending FDA clearance. Other products may be developed through the Know Labs Technology License (KTL) program, potentially without requiring prior FDA approval.

Industry Context

The announcement positions Know Labs within the growing market for non-invasive monitoring technologies, particularly in the healthcare sector. The OTCQB listing aims to provide increased visibility and access to U.S. investors, which is crucial for development-stage companies.

Comparison to Industry Standards

• Know Labs' RFDS technology competes with other non-invasive monitoring technologies, such as those developed by Dexcom and Abbott in the continuous glucose monitoring (CGM) space.
• Unlike traditional CGM systems that require sensors inserted under the skin, Know Labs aims to provide a completely non-invasive solution.
• The OTCQB listing is a common step for companies seeking to increase their visibility and access to capital, similar to other small-cap and development-stage companies in the healthcare and technology sectors.

Stakeholder Impact

• Shareholders may benefit from increased liquidity and potential valuation improvements due to the OTCQB listing.
• The company's employees may see increased opportunities as the company grows.
• Customers could benefit from the development of non-invasive monitoring technologies.
• The company's suppliers and creditors may see increased business opportunities as the company expands.

Next Steps

• Obtain FDA clearance for the non-invasive glucose monitor.
• Continue developing other products through the Know Labs Technology License (KTL) program.
• Maintain compliance with OTCQB requirements, including financial reporting and annual verification.

Key Dates